THE ADAPTABLE STUDY

In this trial, 15,000 patients from 40 centers across the U.S. were self-enrolled and self-randomized between 2016 & 2019. The Participants were of median age of 67 years With 35.3% had a history of myocardial infarction (MI) and 53% had coronary revascularization within the previous five years. The Results showed after median 26 months of follow-up were as follows No significant difference in the primary effective outcome of all-cause death, MI, or stroke OR Primary safety outcome of major bleeding requiring blood transfusion at 12 months. But there was a high rate of dose switching and discontinuation in patients on a higher dose of Aspirin. Thus this study is very illustrative of fact that low dose Aspirin is equally effective as high dose, and the switch over and discontinuation may be due to GI. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.